Ensemble and Alexion Initiate Collaboration
News Jul 26, 2013
Ensemble Therapeutics has announced the initiation of a drug discovery collaboration with a subsidiary of Alexion Pharmaceuticals, Inc., the global biopharmaceutical company focused on developing and commercializing life-transforming therapies for patients with life-threatening, ultra-rare disorders.
The collaboration will deploy Ensemble’s proprietary drug discovery platforms for several undisclosed drug targets identified by Alexion to create highly innovative small molecule therapeutic candidates.
Under the terms of the collaboration, Ensemble will screen its Ensemblin™ collection of more than ten million macrocycles against several disease drug targets specified by Alexion, utilizing Ensemble’s extensive medicinal chemistry capabilities to discover new small molecule clinical candidates.
Alexion will have the exclusive worldwide rights to develop and commercialize candidates arising from the collaboration. Other terms of the agreement were not disclosed; Ensemble will receive an upfront payment and research support, and can earn additional payments upon the achievement of certain development and commercial milestones.
“Ensemble is thrilled to support Alexion’s cutting edge scientific and clinical programs with our ever increasing capability for macrocycle-based drug discovery,” said Dr. Michael D. Taylor, CEO of Ensemble Therapeutics.
“This new collaboration with a leading biopharmaceutical innovator focused on rare diseases speaks to the breadth of utility of Ensemble’s discovery platforms to address clinically important yet challenging drug targets,” Dr. Taylor added.
“Alexion looks forward to a productive collaboration with Ensemble as we seek to broaden the number of pathways toward developing potentially transformative first-in-class drug candidates for patients with selected severe and life-threatening ultra-rare disorders,” said Martin Mackay, PhD, Executive Vice President, Head of Global R&D at Alexion. “This is a promising addition to our development initiatives as we seek to further expand our product portfolio.”
Two Studies Provide Significant Hope in the Fight Against Antibiotic ResistanceNews
Two recent studies led by the University of Bristol provide significant new hope in the fight against antibiotic resistance.READ MORE
Diabetic Ketoacidosis Assay Collaboration Between Ortho Clinical Diagnostics and EKF DiagnosticsNews
EKF’s Beta-Hydroxybutyrate LiquiColor® Assay for detection of predominant ketone body now available on Ortho’s VITROS® 4600 Chemistry System and VITROS® 5600 Integrated System.READ MORE